Sunitinib (Sutent)
Also known as Sutent
Sunitinib (marketed as Sutent by Pfizer, and previously known as SU11248) is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications.
Source: WikipediaEstimated Total Cost: $5599.52 for an average of 28 days supply
What is it prescribed for?
Patients are most commonly prescribed sunitinib to treat kidney cancer, metastatic cancer, blastomycosis, and rabies.
What drug interactions are known?
Do not take sunitinib if you are taking any of the following:
Critical Interactions
Significant Interactions
Loading...